Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology.
OBJECTIVE
Tissue deposits of the anti-arrhythmic drug amiodarone are a major source of side effects (skin discoloration, etc.). We addressed the mechanism of the concentration of amiodarone in cells, and characterized the resulting vacuolar cytopathology and its evolution towards macroautophagy.


METHODS
Sequestration of amiodarone in human cells (macrophages, smooth muscle cells, HEK 293a cells) was evaluated using its violet fluorescence and cytopathology using GFP-conjugated subcellular markers. Autophagic signalling was probed by immunoblotting for the effector protein LC3. A patient biopsy of amiodarone-induced blue-gray skin discoloration was investigated for the presence of macroautophagy (immunofluorescence for LC3).


RESULTS
Most of the amiodarone (1-20 microM, 4-24 h) captured by cultured cells (macrophages were most avid) was present in enlarged vacuoles. The specific vacuolar ATPase (V-ATPase) inhibitors, bafilomycin A1 or FR167356, prevented vacuolization and drug uptake. Vacuoles in HEK 293a cells were positive for markers of late endosomes and lysosomes (GFP-Rab7, -CD63) and for an effector of macroautophagy, GFP-LC3. The vacuoles accumulated endogenous LC3 and filled with lipids (Nile red staining) following longer amiodarone treatments (> or =24 h). The electrophoretic mobility of both GFP-LC3 and endogenous LC3 changed, showing activation in response to amiodarone. Paraffin tissue sections of the pigmented skin exhibited granular LC3 accumulation in superficial dermis macrophages.


CONCLUSIONS
Vacuolar sequestration of amiodarone occurs at concentrations close to therapeutic levels, is mediated by V-ATPase and evolves towards persistent macroautophagy and phospholipidosis. This cytopathology is not cell type specific, but tissue macrophages appear to be particularly susceptible.
Morissette
G
G
Centre de Recherche en Rhumatologie et Immunologie, Centre Hospitalier Universitaire de Québec, Québec QC, Canada.
Ammoury
A
A
Rusu
D
D
Marguery
M C
MC
Lodge
R
R
Poubelle
P E
PE
Marceau
F
F
D000328:Adult; D000638:Amiodarone / Q000009:adverse effects* / Q000378:metabolism; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000378:metabolism; D001343:Autophagy; D001549:Benzamides / Q000494:pharmacology; D001572:Benzofurans / Q000494:pharmacology; D002478:Cells, Cultured; D006801:Humans; D018942:Macrolides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D008297:Male; D008875:Middle Aged; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D025262:Vacuolar Proton-Translocating ATPases / Q000037:antagonists & inhibitors / Q000502:physiology*; D014617:Vacuoles / Q000187:drug effects / Q000378:metabolism*
D000889:Anti-Arrhythmia Agents; D001549:Benzamides; D001572:Benzofurans; C495452:FR 167356; D018942:Macrolides; C040929:bafilomycin A1; D025262:Vacuolar Proton-Translocating ATPases; D000638:Amiodarone